Flapless procedure corrects presbyopia


Intrastromal treatment optimal for patients with mild hyperopia, has strict indications

Flapless intrastromal correction of presbyopia (IntraCor) with a femtosecond laser (Femtec 520F, Technolas Perfect Vision) provides good presbyopic correction with slight decreases in distance vision. However, the indications for the monovision procedure are strict and it provides the optimal results in patients with mild hyperopia.

Dr Erik L. Mertens, FEBOphth, presented his findings at the annual meeting of the American Society of Cataract and Refractive Surgery.

The technique

The femtosecond laser is an 80KHz device. When performing the presbyopia treatment, 40 KHz is used. Using this procedure, five microscopic, concentric ring patterns are created in the stroma that alter the corneal curvature and correct presbyopia. The creation of three and six rings is being investigated but is not yet approved. Currently, one eye is treated at a time, and the nondominant eye is treated first, explained Dr Mertens.

Immediately postoperatively, air bubbles are visible in the cornea and almost resolve by 2 hours after the procedure; by 1 month postoperatively the effects of the procedure are barely visible. Dr Mertens showed on optical coherence tomography images that there is a safety zone between Descemet's membrane and the area treated with the procedure.

Probably the most important aspect of this procedure is centration. Topographic evaluation shows central steepening that, according to Dr Mertens, works very well, when the treatment is well centred.

"With this procedure, centration is extremely important," he said.

In Dr Merten's hands, this procedure is best performed in patients who have refractive errors of +0.5 to +1.25 D. When he initially treated patients who had plano presbyopia, the patients were unhappy postoperatively with the slight myopic shift and resultant mild loss of their distance visual acuity. After the surgery, patients who had mild hyperopia had some glare and halos, and some patients developed dry eye, but these may not be related to the procedure.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.